Anders Gustavsson
Overview
Explore the profile of Anders Gustavsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Handels R, Herring W, Kamgar F, Aye S, Tate A, Green C, et al.
Value Health
. 2024 Oct;
PMID: 39384068
Objectives: Decision-analytic models assessing the value of emerging Alzheimer's disease (AD) treatments are challenged by limited evidence on short-term trial outcomes and uncertainty in extrapolating long-term patient-relevant outcomes. To improve...
2.
Bergman I, Franke Foyen L, Gustavsson A, Van den Hurk W
Scand J Psychol
. 2024 Jul;
66(1):1-14.
PMID: 39072723
The present study aimed to establish test-retest reliability and investigate practice effects of the Mindmore cognitive assessment tool, a digital adaptation of traditional pencil and paper tests designed for self-administration....
3.
Jonsson L, Ivkovic M, Atri A, Handels R, Gustavsson A, Hviid Hahn-Pedersen J, et al.
Alzheimers Res Ther
. 2024 Feb;
16(1):48.
PMID: 38424559
Background: The clinical meaningfulness of the effects of recently approved disease-modifying treatments (DMT) in Alzheimer's disease is under debate. Available evidence is limited to short-term effects on clinical rating scales...
4.
Olofsson Bagge R, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, et al.
Ann Surg
. 2024 Feb;
PMID: 38420778
Objective: To investigate overall survival (OS) and health-related quality of life (HRQOL) of first-line isolated hepatic perfusion (IHP) compared to best alternative care (BAC) for patients with uveal melanoma liver...
5.
Stubhaug A, Hansen J, Hallberg S, Gustavsson A, Eggen A, Nielsen C
Eur J Pain
. 2024 Jan;
28(6):960-977.
PMID: 38214661
Background: Chronic pain is a condition with severe impact on many aspects of life, including work, functional ability and quality of life, thereby reducing physical, mental and social well-being. Despite...
6.
Crowell V, Reyes A, Zhou S, Vassilaki M, Gsteiger S, Gustavsson A
BMC Neurol
. 2023 Aug;
23(1):302.
PMID: 37580727
Background: Evidence on the relative risk of death across all stages of Alzheimer's disease (AD) is lacking but greatly needed for the evaluation of new interventions. We used data from...
7.
Aye S, Jonsson L, Gustavsson A, Tate A, Ptacek S, Eriksdotter M
Alzheimers Dement (Amst)
. 2023 Apr;
15(1):e12422.
PMID: 37009338
Introduction: We examined (1) the magnitude of mortality attributed to Alzheimer's disease (AD), and (2) the effect of mortality in cost-effectiveness modeling of hypothetical disease-modifying treatment (DMT) in AD. Method:...
8.
Landeiro F, Morton J, Gustavsson A, Potashman M, Lecomte P, Belger M, et al.
Alzheimers Dement (N Y)
. 2022 Oct;
8(1):e12360.
PMID: 36313968
The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD...
9.
Handels R, Green C, Gustavsson A, Herring W, Winblad B, Wimo A, et al.
Alzheimers Dement
. 2022 Oct;
19(5):1800-1820.
PMID: 36284403
Introduction: The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's...
10.
Frolich L, van der Flier W, Gustavsson A, Rossini P, Holzapfel D
Alzheimers Dement
. 2022 Sep;
19(1):373-374.
PMID: 36074640
No abstract available.